New treatment for cervical cancer recommended in Europe3 Mar 2015
European regulators adopted a positive opinion for bevacizumab (trade name: Avastin), which is now a treatment option for cervical cancer patients.
The recommended variation concerns the use of drug Avastin in combination with chemotherapy as a treatment for women with an advanced form of cancer of the cervix.
Details of the decision
The new indication is described as follows: “Bevacizumab, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix.”
Avastin is already approved in Europe to treat advanced stages of breast cancer, colorectal cancer, non-small cell lung cancer, kidney cancer and ovarian cancer.
Detailed conditions for the use of this product will be described in the updated summary of product characteristics, which will be published in the revised European public assessment report, and will be available in all official European Union languages after the variation to the marketing authorization has been granted by the European Commission.
Source: European Society for Medical Oncology